Top

Published in:

01-04-2008 | Conference Paper

Personalized systemic treatment for breast cancer patients: is it a reality?

Authors: Chikako Shimizu, Yasuhiro Fujiwara

Published in: Breast Cancer | Issue 2/2008

Abstract

There is a clinical demand for tools that could distinguish patients who may benefit or suffer from particular systemic treatments. High throughput technologies such as DNA microarray are anticipated as comprehensive tools for development of accurate predictive markers of treatment outcome. Although technical and statistical problems still exist in pharmacogenomic research, rigorous efforts have been made to realize treatment individualization. Clinicians should be prepared for the future use of these new technologies in the clinic through discussion involving patients and various health-care providers.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. Lancet. 2005;365:1665–6.CrossRef

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evince E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local-recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106.PubMed

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRef

Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbech SH, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–91.PubMed

Sorlie T, Perou CM, Tibishirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor sub- classes with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. Multigene assay to predict recurrence of tamoxifen treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRef

Van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRef

Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene-signature from tumorgenic breast cancer cells. N Engl J Med. 2007;356:217–26.PubMedCrossRef

10.

Van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRef

11.

Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164:35–42.PubMed

12.

http://www.eortc.be/services/unit/mindact/MINDACT_websiteii.asp

13.

http://www.cancer.gov/clinicaltrials/EORTC-10041

14.

http://www.cancer.gov/newscenter/pressreleases/TAILORxRelease

15.

http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1

16.

Ach RA, Floore A, Curry B, Lazar V, Glas AM, Pover R, et al. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnositic tools. BMJ Genomics. 2007;8:148–57.CrossRef

17.

Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer N Eng J Med. 2006;355:560–9.CrossRef

18.

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54.PubMedCrossRef

19.

Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group Study. J Clin Oncol. 1992;10:1284–91.PubMed

20.

Vogel Cl, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.PubMedCrossRef

21.

Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006;24:2428–36.

22.

Seve P, Mackey J, Issac S, Tredan O, Souquet PJ, Perol M, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005;4:2001–7.PubMedCrossRef

23.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med. 2005;353:1673–84.PubMedCrossRef

24.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Unch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Eng J Med. 2005;353:1659–72.CrossRef

25.

Chang JC, Wooten EC, Tsimeizon A, Hilsenbeck SG, Gutierrrez MC, Elledge R, et al. Gene expression profiles predicts therapeutic response to docetaxel (Taxotere) in breast cancer patients. Lancet. 2003;362:362–9.PubMedCrossRef

26.

Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22:2284–93.PubMedCrossRef

27.

Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol. 2005;23:7232–41.CrossRef

28.

Hudis CA. Trastuzumab-mechanisim of action and use in clinical practice. N Engl J Med. 2007;357:39–51.PubMedCrossRef

29.

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6.PubMed

30.

Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer. 2002;86:1028–33.PubMedCrossRef

31.

Clinical implication of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25:3837–45.

32.

Rogowski W. Current impact of gene technology on healthcare: a map of economic assessments. Health Policy. 2007;80:340–57.PubMedCrossRef

Title: Personalized systemic treatment for breast cancer patients: is it a reality?
Authors: Chikako Shimizu
Yasuhiro Fujiwara
Publication date: 01-04-2008
Publisher: Springer Japan
Published in: Breast Cancer / Issue 2/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-008-0029-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer

Bilateral breast MR imaging: is it superior to conventional methods for the detection of contralateral breast cancer?

Screening ultrasonography revealed 15% of mammographically occult breast cancers

Breast cancer: individualized diagnosis for tailored treatment

Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance

Screening and diagnosis of breast cancer in augmented women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer